News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Press Releases

Epigenomics AG: No operational reasons for sharp decline in share price

DGAP-News: Epigenomics AG / Key word(s): Statement/Capital Increase 04.11.2019 / 20:55 The issuer is solely responsible for the content of this announcement. Epigenomics AG: No operational reasons for sharp decline in share price Berlin (Germany) and San Diego, CA (U.S.A.), 4 November, 2019 – The Epigenomics share price today recorded a decline of around 16% […]

Read more

Epigenomics AG: Results from Microsimulation Model to be presented at renowned health conference

DGAP-News: Epigenomics AG / Key word(s): Study results/Miscellaneous 02.10.2019 / 11:05 The issuer is solely responsible for the content of this announcement. Epigenomics AG: Results from Microsimulation Model to be presented at renowned health conference Berlin (Germany) and San Diego, CA (U.S.A.), October 2, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY) today announced that […]

Read more

Epigenomics AG Highlights Operational Achievements and Reports Financial Results for First Six Months 2019

DGAP-News: Epigenomics AG / Key word(s): Half Year Results/Quarter Results 07.08.2019 / 08:00 The issuer is solely responsible for the content of this announcement. Epigenomics AG Highlights Operational Achievements and Reports Financial Results for First Six Months 2019 Berlin (Germany) and San Diego, CA (U.S.A.), August 7, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY, […]

Read more

Study Published in American Health Drug Benefits Suggests that Non-Invasive Screening Methods, Including Epi proColon, Could Be A Cost-Effective Option To Help Achieve Target U.S. Colorectal Cancer Screening Rates

DGAP-News: Epigenomics AG / Key word(s): Study results/Study 24.07.2019 / 21:42 The issuer is solely responsible for the content of this announcement. Study Published in American Health Drug Benefits Suggests that Non-Invasive Screening Methods, Including Epi proColon, Could Be A Cost-Effective Option To Help Achieve Target U.S. Colorectal Cancer Screening Rates Berlin, 24 July 2019 […]

Read more

Epigenomics AG Receives MedTech Outlook’s 2019 Top 10 In-Vitro Diagnostics Award

DGAP-News: Epigenomics AG / Key word(s): Miscellaneous 11.07.2019 / 14:30 The issuer is solely responsible for the content of this announcement. Epigenomics AG Receives MedTech Outlook’s 2019 Top 10 In-Vitro Diagnostics Award Company recognized for its leadership in advancing blood-based tests to diagnose cancer Berlin (Germany) and San Diego, CA (U.S.A.), July 11, 2019 – […]

Read more

Epigenomics AG: New Clinical Data Support the Utility of Epi proColon(R) Blood Test for Colorectal Cancer (CRC) Screening in Patients with Lynch Syndrome (LS), the Most Common Hereditary CRC Syndrome

DGAP-News: Epigenomics AG / Key word(s): Study results/Scientific publication 17.06.2019 / 14:00 The issuer is solely responsible for the content of this announcement. New Clinical Data Support the Utility of Epi proColon Blood Test for Colorectal Cancer (CRC) Screening in Patients with Lynch Syndrome (LS), the Most Common Hereditary CRC Syndrome   Minimally-invasive blood test […]

Read more